# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Cyclo Therapeutics (NASDAQ:CYTH) with a Buy and maintains ...
Cyclo Therapeutics (NASDAQ:CYTH) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of ...
https://register.epo.org/application?number=EP19805439
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Cyclo Therapeutics (NASDAQ:CYTH) with a Buy and maintains ...
TransportNPC™ is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and...
Cyclo Therapeutics (NASDAQ:CYTH) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(...
HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Cyclo Therapeutics (NASDAQ:CYTH) with a Buy rat...
Ascendiant Capital analyst Lucas Ward initiates coverage on Cyclo Therapeutics (NASDAQ:CYTH) with a Buy rating and announces...